Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105144 · ClinicalTrials.gov registry record · Phase 3
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
A Phase 3 study of Candidemia and Candidiasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 611
- Enrollment target
- 20
- Study locations
NCT00105144 is a Phase 3 study of Candidemia and Candidiasis that has completed, run by Astellas Pharma. The registered enrollment target is 611 participants, above the 338-participant average among 8 other Candidemia trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00105144, a Phase 3 study of Candidemia and Candidiasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 611 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
Conditions Studied
Interventions
- DRUG Caspofungin
- DRUG Micafungin
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - San Francisco
Georgia
- - Atlanta
- - Augusta
- - Augusta
Illinois
- - Chicago
- - Chicago
- - Maywood
Colorado
- - Denver
- - Denver
Florida
- - Bay Pines
- - Miami
Indiana
- - Beech Grove
- - Evansville
Iowa
- - Des Moines
- - Iowa City
Alabama
- - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105144
The ClinicalTrials.gov registry entry for NCT00105144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 338-participant average among 8 other Candidemia trials with a reported enrollment target (81% higher). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Candidemia appearing as the primary indexed condition, and to 2 interventions - of which Caspofungin is the first listed.
NCT00105144 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00105144 about?
NCT00105144 is a clinical study titled "Study of Micafungin in Patients With Invasive Candidiasis or Candidemia". The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
What is the current status of trial NCT00105144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 611 participants. The study started on 2004-09. Estimated completion is 2006-04.
What conditions does trial NCT00105144 study?
This clinical trial studies the following conditions: Candidemia, Candidiasis.
What interventions are being tested in trial NCT00105144?
The interventions under investigation include: Caspofungin (DRUG), Micafungin (DRUG).
Who is sponsoring clinical trial NCT00105144?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00105144 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.